-1.31%
-6.37%
-9.67%
-39.15%
-23.58%
-25.84%
17.89%
AI Spotlight on ICLR
Company Description
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services.
The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services.It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Market Data
| Last Price | 199.08 |
| Change Percentage | -1.31% |
| Open | 202.65 |
| Previous Close | 201.72 |
| Market Cap ( Millions) | 16436 |
| Volume | 494485 |
| Year High | 347.72 |
| Year Low | 183.38 |
| M A 50 | 208.54 |
| M A 200 | 277.63 |
Financial Ratios
| FCF Yield | 7.41% |
| Dividend Yield | 0.00% |
| ROE | 7.87% |
| Debt / Equity | 36.60% |
| Net Debt / EBIDTA | 169.69% |
| Price To Book | 1.69 |
| Price Earnings Ratio | 22.05 |
| Price To FCF | 13.5 |
| Price To sales | 1.98 |
| EV / EBITDA | 11.37 |
News
- Feb -01 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR
- Jan -31 - Baron Small Cap Fund: Q4 2024 Top Contributors And Detractors
- Jan -30 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR
- Jan -30 - ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies
- Jan -29 - ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
- Jan -26 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR
- Jan -24 - ICON Energy Corp. Announces Closing of Upsized $12.0 Million Public Offering
- Jan -24 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR
- Jan -23 - ICON Energy Corp. Announces Pricing of Upsized $12.0 Million Public Offering
- Jan -22 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR
- Jan -18 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR
- Jan -10 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company - ICLR
- Jan -08 - Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders – ICON Survey
- Jan -07 - ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -31 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company - ICLR
- Dec -29 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company - ICLR
- Dec -26 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company - ICLR
- Dec -23 - ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
- Dec -20 - ICON Public Limited Company (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- Dec -20 - New Strong Sell Stocks for December 20th
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Outsourced Development Services
Expected Growth : 7 %
What the company do ?
ICON's Outsourced Development Services provide pharmaceutical, biotechnology, and medical device companies with customized clinical development solutions, from study design to regulatory submission.
Why we expect these perspectives ?
ICON's 7% growth in Outsourced Development Services is driven by increasing demand for clinical trial outsourcing, expansion into emerging markets, and strategic partnerships. Additionally, the company's expertise in orphan diseases and rare conditions, as well as its investments in digital technologies, have contributed to its growth momentum.
Icon Public Limited Company Products
| Product Range | What is it ? |
|---|---|
| Clinical Research Operations | ICON provides clinical research operations services to pharmaceutical, biotechnology, and medical device companies, including site management, patient recruitment, and data management. |
| Lab Services | ICON offers laboratory services, including bioanalytical testing, biomarker development, and central laboratory services, to support clinical trials and drug development. |
| Imaging Services | ICON provides medical imaging services, including image acquisition, analysis, and interpretation, to support clinical trials and drug development. |
| Regulatory and Consulting Services | ICON offers regulatory consulting services, including regulatory strategy, submission, and compliance, to support pharmaceutical, biotechnology, and medical device companies. |
| Functional Service Provider (FSP) Solutions | ICON provides functional service provider solutions, including customized outsourcing solutions, to support pharmaceutical, biotechnology, and medical device companies. |
| Innovative Medicines and Early Development | ICON provides innovative medicines and early development services, including translational medicine, early phase clinical trials, and proof-of-concept studies. |
ICON Public Limited Company's Porter Forces
Threat Of Substitutes
The threat of substitutes for ICON Public Limited Company is medium due to the presence of alternative products and services in the market.
Bargaining Power Of Customers
The bargaining power of customers for ICON Public Limited Company is high due to the availability of alternative products and services, and the ability of customers to switch to competitors.
Bargaining Power Of Suppliers
The bargaining power of suppliers for ICON Public Limited Company is low due to the company's large scale of operations and its ability to negotiate with suppliers.
Threat Of New Entrants
The threat of new entrants for ICON Public Limited Company is medium due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.
Intensity Of Rivalry
The intensity of rivalry for ICON Public Limited Company is high due to the presence of several competitors in the market, and the need to constantly innovate and differentiate to stay ahead.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 29.20% |
| Debt Cost | 8.71% |
| Equity Weight | 70.80% |
| Equity Cost | 9.85% |
| WACC | 9.51% |
| Leverage | 41.25% |
ICON Public Limited Company : Quality Control
ICON Public Limited Company passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| EL.PA | EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses … |
| NOVO-B.CO | Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
| LONN.SW | Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
EssilorLuxottica
A-Score
1-Year Total Return ->
🥉
GSK
A-Score
1-Year Total Return ->
4
Novo Nordisk
A-Score
1-Year Total Return ->
5
Lonza
A-Score
1-Year Total Return ->
6
